UMDNJ Group Develops 'Super' Selective Primer Tech for Low-Level qPCR-Based Mutation Detection | GenomeWeb

SAN FRANCISCO — Researchers from the University of Medicine and Dentistry of New Jersey and New Jersey Medical School this week unveiled a new qPCR-based mutation-detection chemistry at Cambridge Healthtech Institute's Molecular Medicine Tri-Conference held here.

The technology, called SuperSelective Primers, was developed in the laboratory of Fred Kramer, a researcher at UMDNJ, NJMS, and the Public Health Research Institute Center, which is affiliated with the two medical schools.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: parent-of-origin effects, framework to uncover clinically important mutations from whole genome sequence data, and more.

A survey of Cincinnati schoolchildren finds teenagers want to know their genetic predisposition to disease, LiveScience reports.

More and more universities are helping their researchers patent their inventions, the Los Angeles Times reports.

Cancer Research UK unveils seven 'grand challenges' that it will fund researchers to tackle.